



## SUMMARY OF CANCER TREATMENT

This "Survivorship Passport" is a short summary extracted from the information reported in the medical record. It describes the disease and its clinical course as well the treatments you received. This document does not replace the medical record that is always available at our center. This document does not replace the medical record which is always available at the treatment center in case of need

Passport Number: |

### PERSONAL DATA

Name	Lastname
Date of birth	03/07/2011
Sex	Male
Mobile phone	

### DIAGNOSIS

Date of diagnosis	23/09/2015
Institution	Vilniaus universiteto ligoninė Santaros klinikos
Classification	3 - Malignant, primary site
Diagnosis	Precursor B-cell lymphoblastic leukemia
Diagnosis (morphology)	Precursor B-cell lymphoblastic leukemia
Diagnosis description	Ūminė pre-B limfoblastinė leukemija, standartinės rizikos grupė, CNS 1
Site	Bone marrow
Laterality	Not applicable (Tumor in a not paired site)
Metastatic	No

### OTHER DISEASES

Hereditary Cancer Predisposition Syndrome or medical condition cancer associated	22Q11.1-Q11.22 DUPLIKACIJOS SINDROMAS
Other medical conditions, not cancer associated	Stebimas kardiologų dėl įgimtos širdies ydos (2 sav. amžiuje operuotas dėl PPD, esant pilnam anomaliai plaučių venų drenažui). Dėl netinkamos organų išsidėstymo pozicijos operuotas žarnynas, skrandis, apendicitas. Astigmatizmas, nešioja akinius, operuota akis dėl žvairumo, sekamas oftalmologo. Nustatytas mišrus specifinis raišys sutrikimas. Nepakankamas kūno svoris. Netaisyklinga laikysena, čiurnų kontraktūros.

### FIRST-LINE TREATMENTS

The treatment has been executed following	A trial/protocol: PAGAL NOPHO ALL-2008 PROTOKOLĄ
Group/Arm/Randomization	STANDARTINĖ RIZIKOS GRUPĖ
Summary of major treatments	Chemotherapy Yes HSCT No Radiotherapy No Major Surgery No
Progression/Relapse during first-line treatment	No
Date of first elective end of treatment	27/03/2018

### CHEMOTHERAPY

FIRST LINE		
Start date	23/09/2015	End date 27/03/2018
ANTINEOPLASTIC AGENTS		
Drug name	Total cumulative dose	Measure unit
Methotrexate	40000 (Dose given)	mg/m2
Mercaptopurine	1400 (Dose given)	mg/m2
Thioguanine	840 (Dose given)	mg/m2
Cytarabine	600 (Dose given)	mg/m2
Vincristine	32 (Dose given)	mg/m2
Doxorubicin	80 (Dose given)	mg/m2
Intrathecal injections ( 13 )	METOTREKSATAS	
OTHER TREATMENTS		
Other treatments	ILGALAIKIS KORTIKOSTEROIDŲ VARTOJIMAS, PEG-ASPARAGINAZĖ, PALAIKYMUI 6-MERKAPTOPURINAS, METOTREKSATAS PO	

OTHER RELEVANT CLINICAL INFORMATION AND EVENTS

CLINICAL COURSE	
Important toxicity during treatment	Yes
Toxicity number	1
First toxicity	
Date of event	04/04/2016
Description	Vaistų sukelta periferinė neuropatija
Resolved	Yes
CVC positioning	Yes (Removed)
If yes, specify the site	v.subclavia sin.
Catheter-related thrombosis	No
Transfusion	Yes
Last transfusion date	
Fertility preservation	No
Other treatments	Trimetoprimas/sulfametoksazolas intermituojančiu režimu PO

RECOMMENDATIONS FOR FOLLOW-UP

FOLLOW-UP RECOMMENDATIONS:

Here below are listed personalized follow-up recommendations, based on the treatments you received.  
These advices are based on international experience with people who received similar treatments as you. They are meant to prevent and/or diagnose at an early stage possible future complications.

General recommendations:

A healthy lifestyle helps to maintain physical and mental wellbeing, as well as preventing possible diseases such as cardiovascular complications, tumors, and psychological problems. We therefore recommend you to:

- Maintain a normal body weight and engage in regular physical activity
- Eat plenty of fruits and vegetables, and reduce fat, sugar, and salt intake
- Maintain proper dental hygiene
- Avoid excessive sun exposure and remember to use high-protection sunscreen
- Don't smoke and avoid excessive alcohol intake
- Check your blood pressure periodically
- Report to your health care provider any experience of chronic pain, excessive fatigue and/or deterioration of performance in your daily activities (study, work and/or exercise)
- Adhere to all cancer screening programs that will be offered by the health system

The treatment plan created by the "SurPass" Class 1 Medical Device developed from Cineca.

You could be at risk of	Since you was treated with	Therefore it is recommended that
Hypertension		Check blood pressure at least every 2 years and at every medical examination. <b>Comments:</b> 2024-08 AKS normotenzinis
Arrhythmia	- Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2	Perform an ECG after the end of treatment and in any case repeat it after the age of 18, and perform a cardiological assessment if palpitations, dizziness and/or fainting/loss of consciousness occur. <b>Comments:</b> Sekamas vaikų kardiologo dėl ĮŠY, konsultuotas 2024-08
Reduced bone mineral density	- Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment	Maintain an adequate intake of calcium and vitamin D. Sunlight exposure and regular physical activity. Bone densitometry (DEXA) should be performed at least once. In prepubertal or pubertal children, consider postponing DEXA until the end of puberty. Report any persistent back pain and/or accidental fractures to your doctor. <b>Comments:</b> 2024-05 buvo atliktas kaulų mineralinio tankio įvertinimas Dexa scan - kaulų tankis nesumažėjęs
Osteonecrosis	- Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment	Report any persistent bone pain (particularly joint pain) to your doctor.

You could be at risk of	Since you was treated with	Therefore it is recommended that
Liver problems	- Methotrexate - Mercaptopurine or Thioguanine	Regular clinical evaluation for signs and symptoms of liver dysfunction (e.g. hepatomegaly, spider nevi or pruritus). Transaminases, gammaGT and alkaline phosphatase should be measured at least once after treatment ends. In case of an increase in liver enzyme values: if between 1-2 times the normal value: repeat the test within 1 year. If more than 2 times the normal value: repeat the test within 2 months. In case of persistent liver abnormalities: Ask a hepatologist or gastroenterologist for further indications. If there is no obvious explanation (alcohol, medication, obesity) Avoid or use with caution potentially hepatotoxic drugs and supplements Consider immunisation against hepatitis A and B, if not already immune in case of chronic HBV / HCV infections discuss precautions to reduce viral transmission to family and sexual partners <b>Comments:</b> 2024-08 ŠF padidėjusi virš normos 1,03 k, kiti kepenų fermentai - normos ribose
Cataract	- Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment	Have an ophtalmological examination every 5 years <b>Comments:</b> Sekamas oftalmologo dėl astigmatizmo
Dental and oral problems	- Chemotherapy	Careful dental hygiene, and a dental examination in case of oral problems such as caries (tooth decay), abnormal tooth development or dry mouth.
Peripheral neuropathy	- Vinca-Alkaloids	Contact your doctor if you experience persistent pain, tingling, reduced strength and/or sensation in your limbs. <b>Comments:</b> 2024-05 - ENMG kojos motorinių nervų aksonopatijos požymiai (vertinama, kad pakitimai nesusiję su taikytu gydymu), vaikų neurologo sekimas, 2024-08 konsultuotas genetiko

	Planned for
Hypertension	AKS įvertinimas kiekvieno vizito pas gydytoją metu
Arrhythmia	Tolimesnis vaikų kardiologo sekimas pagal numatytą planą
Reduced bone mineral density	Dexa scan po lytinio brendimo
Liver problems	Kepenų fermentai 2025 m.
Dental and oral problems	Odontologo priežiūra

Data are updated to the date of issue of the passport or the date of the last clinical examination certified by the physician.

Passport issued by  
Institution

Date of issue

Signature of the doctor in charge:

